The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
Open accessAbstract
RATIONALE: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. OBJECTIVES: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. METHODS: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. MEASUREMENTS AND MAIN RESULTS: The modified intention-to-treat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. -25.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. CONCLUSIONS: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Self-citationPrevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare Beneficiaries
Adjemian, J., Olivier, K. N., Seitz, A. E., Holland, S. M., & Prevots, D. R. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201111-2016oc · Cited by 690
Self-citationWinthrop, K. L., McNelley, E., Kendall, B., Marshall-Olson, A., Morris, C., Cassidy, M., Saulson, A., & Hedberg, K. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0503oc · Cited by 414
Self-citationMeers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn059 · Cited by 345
Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases
Peloquin, C. A., Berning, S. E., Nitta, A. T., Simone, P. M., Goble, M., Huitt, G. A., Iseman, M. D., Cook, J. L., & Curran-Everett, D. (2004) · Clinical Infectious Diseases · doi:10.1086/420742 · Cited by 270
Hall, L., Doerr, K. A., Wohlfiel, S. L., & Roberts, G. D. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1447-1453.2003 · Cited by 267
van Ingen, J., Bendien, S. A., de Lange, W. C. M., Hoefsloot, W., Dekhuijzen, P. N. R., Boeree, M. J., & van Soolingen, D. (2009) · Thorax · doi:10.1136/thx.2008.110957 · Cited by 266
Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.
Wallace, R. J., Brown, B. A., Griffith, D. E., Girard, W. M., & Murphy, D. T. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.6.8665032 · Cited by 258
Self-citationPhase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Self-citationPulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010
Marras, T. K., Mendelson, D., Marchand-Austin, A., May, K., & Jamieson, F. B. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1911.130737 · Cited by 210
Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.
Wallace, R. J., Brown, B. A., Griffith, D. E., Girard, W. M., Murphy, D. T., Onyi, G. O., Steingrube, V. A., & Mazurek, G. H. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.5.8173775 · Cited by 192
Self-citationInhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease
Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., Zalewski, C. K., Folio, L. R., Siegelman, J. R., Shallom, S., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201307-231oc · Cited by 176
Self-citationBrown-Elliott, B. A., Iakhiaeva, E., Griffith, D. E., Woods, G. L., Stout, J. E., Wolfe, C. R., Turenne, C. Y., & Wallace, R. J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01612-13 · Cited by 173
Self-citationMirsaeidi, M., Machado, R. F., Garcia, J. G. N., & Schraufnagel, D. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091879 · Cited by 159
When and how to treat pulmonary non‐tuberculous mycobacterial diseases
Thomson, R. M., & Yew, W.-W. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01408.x · Cited by 108
Rose, S. J., Neville, M. E., Gupta, R., & Bermudez, L. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108703 · Cited by 107
Self-citationOkusanya, Ó. O., Bhavnani, S. M., Hammel, J., Minic, P. B., Dupont, L., Forrest, A., Mulder, G.-J., Mackinson, C., Ambrose, P. G., & Gupta, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00872-08 · Cited by 104
Self-citationImpaired health-related quality of life in pulmonary nontuberculous mycobacterial disease
Mehta, M., & Marras, T. K. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.08.004 · Cited by 101
Therapy of refractory nontuberculous mycobacterial lung disease
Griffith, D. E., & Aksamit, T. R. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283511a64 · Cited by 93
Self-citationSemiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease
Griffith, D. E., Adjemian, J., Brown‐Elliott, B. A., Philley, J. V., Prevots, D. R., Gaston, C., Olivier, K. N., & Wallace, R. J. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0444oc · Cited by 81
Self-citationO’Connell, M. L., Birkenkamp, K. E., Kleiner, D. E., Folio, L. R., Holland, S. M., & Olivier, K. N. (2011) · CHEST Journal · doi:10.1378/chest.11-0425 · Cited by 55
Self-citationIakhiaeva, E., McNulty, S., Brown‐Elliott, B. A., Falkinham, J. O., Williams, M. D., Vasireddy, R., Wilson, R. W., Turenne, C. Y., & Wallace, R. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02443-12 · Cited by 43
Self-citationSerial trough and peak amikacin levels in plasma as predictors of nephrotoxicity
Contreras, A., Gamba, G., Cortés, J., Santiago, Y., Nares, F., Jiménez‐Sánchez, G., Bobadilla, J. R., López, G., Valadez, A., & Espinosa, A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.973 · Cited by 17
Cited by
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00535-2020 · Cited by 924
Self-citationDaley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa241 · Cited by 890
Self-citationDaley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Self-citationHaworth, C. S., Banks, J., Capstick, T., Fisher, A. J., Gorsuch, T., Laurenson, I. F., Leitch, A., Loebinger, M. R., Milburn, H. J., Nightingale, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210927 · Cited by 785
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
Metadata
- Authors
- Olivier, K. N., Griffith, D. E., Eagle, G., McGinnis, J. P., Micioni, L., Liu, K., Daley, C. L., Winthrop, K. L., Ruoss, S., Addrizzo-Harris, D. J., Flume, P. A., Dorgan, D., Salathe, M., Brown-Elliott, B. A., Gupta, R., & Wallace, R. J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-15
- Volume
- 195
- Issue
- 6
- Pages
- 814-823
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2532369118
- Cited by
- 254
- References
- 24
- FWCI
- 28.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.